anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis has a systemic inflammatory response syndrome caused by infection. While neutrophils play contradictory roles in different stages of sepsis. Neutrophils have been proven to play an antibacterial role by producing neutrophil extracellular traps (NETs). Although the NET is beneficial to bacteria resistance, abnormal NET increases tissue damage. The complement C5a receptor 1 (C5ar1) is a gene related to strong inflammatory reactions and is found to be associated with inflammatory factors. This study found that there were 45 down-regulated genes and 704 up-regulated genes in sepsis rats by transcriptome sequencing. And those genes were significantly related to inflammation and immunity by GO and KEGG enrichment analysis involving the chemokine signaling pathway, the Toll-like receptor (TLR) signaling pathway, and the Fc gamma R-mediated phagocytosis. Additionally, the C5ar1 gene was significantly upregulated with interesting potential in sepsis and used for further study. This study used cecum ligation and puncture (CLP) rats that were respectively injected intravenously with PBS or the lentivirus vector to explore the effect of C5ar1 on CLP rats. It demonstrated that silenced- C5ar1 inhibited the ALT, AST, BUN, and CREA levels, improved the lung and spleen injury, and reduced the TNF-α, IL-6, IL-1β, IL-10, cf-DNA, and cfDNA/MPO levels. Additionally, silenced C5ar1 inhibited the TLR2, TLR4, and peptidylarginine deiminase 4 expression levels, which suggested the improvement of silenced C5ar1 on sepsis via inhibiting NETs and the TLR signaling pathway. This study provides a basis and new direction for the study of treatment on sepsis.
<P>PROBLEM TO BE SOLVED: To provide a solid composition applicable to a human skin and gellable on contact with water.  <P>SOLUTION: The composition contains hyaluronic acid, very fine inert powder and a small amount of water as essential components. The inert powder is selected from a group consisting of mica, talc, silica, polymethylmethacrylate, lauroyl lysine and corn starch. At least one further component selected from a group consisting of emulsified materials, moistened materials and pharmaceutical materials may be contained. The composition is prepared as a solid flexible thin film and is usable as cosmetics and/or therapeutic purposes.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
Gabapentin enacarbil is a prodrug of gabapentin and, accordingly, its therapeutic effects in RLS and PHN are attributable to gabapentin.

The precise mechanism by which gabapentin is efficacious in RLS and PHN is unknown.

The mechanism of action by which gabapentin is efficacious in PHN is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and mice (e.g., spinal nerve ligation models, spinal cord injury model, acute herpes zoster infection model). Gabapentin also decreases pain-related responses after peripheral inflammation (carrageenan footpad test, late phase of formalin test), but does not alter immediate pain-related behaviors (rat tail flick test, formalin footpad acute phase). The relevance of these models to human pain is not known.

Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. Gabapentin enacarbil and gabapentin have been tested in radioligand binding assays, and neither exhibited affinity for a number of other common receptor, ion channel, or transporter proteins.

In vitro studies have shown that gabapentin binds with high affinity to the α2δ subunit of voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin enacarbil in RLS and PHN is unknown.
Differentiated neuronal cells suitable for transplantation in individuals with a dopamine deficiency are derived from progenitor cells. The progenitor cells are treated with at least one inducing agent such as retinoic acid for a time period sufficient to optimize expression of tyrosine hydroxylase. The cells intended for transplantation are optionally treated with a lithium salt to enhance bcl-2 production and survival. Optionally, the progenitor cells may be co-cultured with Sertoli cells, astrocytes, glial cells, accessory cells or a combination thereof. The transplantation-ready cells are isolated and harvested. The resulting neuronal cells are highly purified and have a phenotype optimized for a dopaminergic deficiency, such as Parkinson's Disease.
BACKGROUND: Postoperative nausea and vomiting occur frequently following thyroid and parathyroid surgery and are associated with worse patient outcomes. We hypothesised that opioid-free propofol anaesthesia would reduce the incidence of postoperative nausea and vomiting compared with opioid-inclusive propofol anaesthesia in patients undergoing these procedures.
METHODS: We conducted a randomised, double-blinded controlled trial in adult patients scheduled to undergo thyroid and parathyroid surgery at two medical centres in mainland China. Patients were allocated randomly (1:1, stratified by sex and trial site) to an opioid-free anaesthesia group (esketamine, lidocaine, dexmedetomidine and propofol) or an opioid-inclusive group (sufentanil and propofol). Propofol infusions were titrated to bispectral index 45-55. Patients received prophylaxis for nausea and vomiting using dexamethasone and ondansetron and multimodal analgesia with paracetamol and flurbiprofen axetil. The primary outcome was the incidence of postoperative nausea and vomiting in the first 48 h after surgery.
RESULTS: We assessed 557 patients for eligibility and 394 completed this trial. The incidence of postoperative nausea and vomiting in the first postoperative 48 h was lower in the opioid-free anaesthesia group (10/197, 5%) compared with opioid-inclusive group (47/197, 24%) (OR (95%CI) 0.17 (0.08-0.35), p < 0.001), yielding a number needed to treat of 5.3. Additionally, opioid-free propofol anaesthesia was associated with a reduced need for rescue anti-emetics, lower rates of hypotension and desaturation after tracheal extubation, and higher patient satisfaction. Time to tracheal extubation was prolonged slightly in the opioid-free group. The two groups had similar postoperative pain scores and 30-day outcomes.
DISCUSSION: Opioid-free propofol anaesthesia reduced postoperative nausea and vomiting in patients undergoing thyroid and parathyroid surgery. An opioid-free anaesthetic regimen can optimise anaesthetic care during thyroid and parathyroid surgery.
Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive, characterized histologically by monoclonal myoblasts present in abundant stromal tissue.The current therapeutic strategy has abandoned primary resection, as recurrences after resection are common and often their phenotype is more infiltrative. Nonsurgical approaches remain suboptimal. For asymptomatic disease, current guidelines suggest an initial period of active surveillance.

The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy. Embolization of desmoid tumors alone, without chemotherapy, on the contrary, has been shown to be inefficient. Doxorubicin is routinely used in the treatment of soft tissue sarcomas and other mesenchymal malignancies. Its use against desmoid fibromatosis is effective but associated with hematologic, gastrointestinal, and cardiac toxicity. Consequently, this drug is reserved for symptomatic, nonresponsive, rapidly growing or life-threatening tumors. The intrinsic hypervascularity of desmoid tissue can be exploited as a conduit to achieve local distribution of Doxorubicin by navigation of a catheter endovascular. Doxorubicin contains a protonated amine group which can establish an ionic bond with the sulfonate present on the surface of microbeads of hydrogel, ensuring embolization and elution of the drug. This process allows high concentrations of Doxorubicin in the target tissue and low concentrations in the systemic circulation.
NEW MATERIAL:A nitrogen-containing polycyclic compound of formula I (R1 and R2 are lower alkyl groups W is O or NH), and its salt. EXAMPLE:cis 16-Methoxycarbonyl-17-iminoeburnan. USE:Useful as remedies for arteriosclerosis and cerebral and coronary blood vessel throubles dur to thrombus, having the vasodilator, antispasmodic, and cerebral metabolism enhancing actions, and useful as an intermediate for the eburnamenin- type alkaloid ester having improved cerebral vasodilator actions. PROCESS:An indoloquinolizine derivative of formula II is reacted with a compound of the formula X-CH2CO2R1 (X is halogen) in a solvent, e.g. dimethylformamide, at 10-70 deg.C, and if necessary hydrolyzed with water or a hydrous alcoholic solvent in the presence of an acid catalyst, e.g. a mineral acid, at 0 deg.C-room temperature to form the compound of formula I.
PROBLEM TO BE SOLVED: To obtain the subject composition which has comprehensive depilatory preventability, hair restoriung facilitative effect and inhibitory effect on dandruff and itch and in addition is useful as a hair growing material capable of directly acting on papilla pili cells and hair follicle epithelial cells by formulating an extract from a specific plant as an active ingredient. SOLUTION: This composition is obtained by formulating an extract from a plant belonging to the family Euphorbiaceae the genus Croton, e.g. preferably Croton birmanicus Mueli Arg. and the like, as an active ingredient preferably in an amount of 0.001-10.0 wt.% on the basis of the dry product. The above extract is obtained by immersing the whole grass, e.g. leaves, stems containing subterranean stems, roots, fruits and barks, into an extracting solvent such as methanol and the like or refluxing it together with the extracting solvent followed by filtration and concentration. This composition can be prepared in dosage forms of tonic, hair cream and mousse.
Appts. for sepg. particles suspended in liq. media comprising an electrophoresis cell with a pair of electrodes a convection column communicating with and between the electrodes of the electrophoresis cell, a device for feeding media into the cell and a device adjacent each electrode for removing desired fractions of particles having the same electric potential from the liq. medium. Used for control of sex of mammalian offspring by sepn. of spermatozoa having X chromosomes to produce males from those with Y chromosomes to produce females. For use in man and for controlled breeding of animals.
The utilisation comprises prolonging the activity and storage stability of thrombocytes in thrombocyte concentrates or preserved blood. The TXA2 blocker is pref. a TXA2 receptor agonist or a TXA synthetase inhibitor or has both activities. Esp. the TXA2 blocker is Sultroban or Daltroban. Sultroban is used in an amt. of more than 8 mg, (10-15 mg) in 400 ml thrombocyte concn. Daltroban is used in an amt. of more than 0.8 mg (1-1.5 mg) in 400 ml thrombocyte concn. USE/ADVANTAGE - The thromboxan TXA2 blockers have an anti aggregatory effect (i.e. avoid promoting activation processes in the thrombocytes in the concn. which may lead to aggregation). The effect in reversible (i.e. removed as soon as the thrombocytes are transferred to the patient, or the thrombocytes may not promote haemostasis). The activity of the TXA2 blockers is selective and undesired side effects are avoided. The addn. of the TXA2 blockers may be varied i.e. may be added to the finished thrombocyte, or during blood donation before leading the blood to the cyta phoresis device or used to treat the thombocyte donor prior to thrombocytapoeisis. The treated thrombocyte concentrates may be used to treat e.g. thrombocytoperic disorders
Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
A method for producing affino-enzymatic cpds. (I) for visual indication of cholesterol on skin surface based on a detecting agent A (which is an affinant of cholesterol) and visualising agent B is claimed characterised in that detecting agent A is selected from a gp. of steroid glycosides contg. as an aglycone a cyclopentanoperhydrophenanthrene fragment of furostanole or 3 to 10 monosaccharides having linear or branched structure or (a) from a gp. of triterpene glycosides contg. an aglycone of alpha - or beta-amyral, lupane, gopane, dammarane, lanostane or holostane series and an oligosaccharide of 2-8 residues having branched or linear structure or (b) from a gp. of hydrophobic proteins capable of discriminately forming complex cpds. with cholesterol or (c) from a gp. of protein toxins capable of discriminately forming complex cpds. with cholesterol and produced from bacteria, marine microorganisms, insects or snakes or (d) from a gp. of polyene antibiotics capable of discriminately forming complex cpds. with cholesterol or (e) from a gp. of enzymes having high affinity for cholesterol, is chemically activated in an aqs. medium at a molar ratio of agent A to activator of 1=1 to 1=10 at a concn. of agent A of 1-2mg/ml, a temp. of 0-25 deg.C. pH of 4-11 for 0.1-24hrs. and to the soln. obtd., visualising agent B selected from acetylcholinesterase, tyrosinase, glucose -6- phosphatedehy drogenase, glucose oxidase, glucosoamylase, galactosidase, peroxidase, alkaline or acid phosphatase, alpha-chymotrypsin or pyrophosphatase, is added at a molar ratio of A : B of 20: 1-1:1 and the soln. is incubated at 0-25 deg.C. for 1-24 hrs.
The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. Exemplary derivatives have the formula
Do not use if the seal on jar is broken. Remove pledget from jar just before use. Use a pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. Keep jar tightly closed when not in use.
PURPOSE:A pack composition, containing gibberellin and if necessary a proteolytic enzyme, and capable of dulling the hue of deposited pigments, e.g. liver spots or freckles. CONSTITUTION:A pack composition containing 0.1-0.5wt% gibberellin, e.g. gibberellin A1 of the formula, and if necessary 0.1-1.0wt% proteolytic enzyme. The gibberellin is capable of dulling the hue of pigments deposited due to the hyperfunction of melanocytes. Any one of proteolytic enzymes, e.g. papain, bromelain or ficin, originating from plant sources, and pepsin, trypsin, chymotrypsin or cathepsin, originating from animal sources may be used as the proteolytic enzyme used together with the gibberellin, and the former is preferred. The gibberellin and proteolytic enzyme can be added to all types of pack compositions, e.g. jelly, pasty or powdery form.
<P>PROBLEM TO BE SOLVED: To provide a compound useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1, and to provide an intermediate therefor.  <P>SOLUTION: The compound is useful for the in vitro study of the role of ADAM-10 (and inhibition thereof) in biological processes. There are included a pharmaceutical composition comprising one or a plurality of ADAM-10 inhibitors in combination with a pharmaceutically acceptable carrier, and a new sulfonyl halide exemplified by formula IX as the intermediate. The composition is useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, there is also included a method for treating forms of the cancer, arthritis, and diseases related to the angiogenesis in which the ADAM-10 plays a critical role.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The effects of low-load exercise with blood flow restriction (BFR) on the ability to voluntarily activate skeletal muscle in people with joint injuries are poorly understood. The aim of our study was to investigate the effects of low-load BFR training on the level of voluntary activation (AL) of the quadriceps femoris muscle assessed using the interpolated twitch technique in people with different knee joint injuries. Thirty-three orthopedic patients assigned to either the BFR group or the SHAM-BFR group participated in the study. Over a period of four weeks, the participants completed 12 training sessions of unilateral knee extension and leg press at 30 RM. The BFR group trained with a pneumatic cuff-induced blood flow restriction (pressure = 120-140 mmHg), while the SHAM-BFR group trained with a sham blood flow restriction (pressure = 20 mmHg) that did not interfere with normal muscle perfusion. The assessment of knee muscle capacity and function consisted of dynamometric measurements of maximal isometric strength and endurance of the knee extensor muscles, level of voluntary muscle activation, surface electromiography, pain intensity and assessment of perceived exertion. All tests and measurements were performed twice, once before the intervention (baseline) and once at the end of the 4-week training period (POST).
Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
In the preparation of detergents, a shale oil fraction boiling within the range 270 DEG  to 360 DEG  C. is reacted with sulphuric acid and neutralized with a metal base to produce metal alkyl sulphates of low solubility in water.  The sulphonation is preferably effected with sulphuric acid of 96-100 per cent strength, in amount from 10-20 per cent, preferably 12-13 per cent by volume of the feed oil, and at a temperature below 20 DEG  C., preferably 5-20 DEG  C.  The alkyl sulphates are separated from the acid sludge and run into excess of metal hydroxide or carbonate solution, e.g. sodium carbonate.  The resulting emulsion is refluxed for say 5 hours at 95 DEG  C. and extracted with, for example, isopropyl alcohol to separate the more volatile unreacted oils.  The separated alcoholic detergent solution is then evaporated to a thin paste containing about 12.5 per cent of sodium alkyl sulphate calculated as C20 H41SO3ONa.ALSO:A detergent composition is prepared by reacting a shale oil distillation fraction boiling within the range 270 DEG  to 360 DEG  C. with sulphuric acid, neutralizing with a metal base to produce metal alkyl sulphates of low solubility in water, and mixing with a filler such as kieselguhr. The sulphonation is preferably effected with sulphuric acid of 96-100 per cent strength, in amount from 10-20 per cent, preferably 12-13 per cent, by volume of the feed oil, and at a temperature below 20 DEG  C., preferably 5-20 DEG  C.  The alkyl sulphates are separated from the acid sludge and run into excess of metal hydroxide or carbonate solution, e.g. sodium carbonate.  The resulting emulsion is refluxed for, say, 5 hours at 95 DEG  C., and extracted with, for example, isopropyl alcohol, to separate the more volatile unreacted oils.  The separated alcoholic detergent solution is evaporated to a thin paste containing about 12.5 per cent of sodium alkyl sulphate calculated as C20H41SO3ONa, which is mixed with a binding agent such as bentonite and a filler such as kieselguhr to form a detergent paste suitable, for example, for cleaning the hands of mineral lubricating oils and sludges, dirt containing weak acids or metallic salts such as zinc chloride, or for cleaning painted surfaces. Mineral oils such as spindle oil, antiseptics, deodorants, and colouring matter may be added.
OBJECTIVE: Elevated level of D-Dimer often indicates a worse prognosis in cerebral infarction. However, there is limited research on this impact within recent small subcortical infarction (RSSI). We aim to explore the role of inflammation and the total magnetic resonance imaging (MRI) burden of cerebral small vessel disease (cSVD) in this process.
METHODS: 384 RSSI patients and 189 matched healthy controls were strictly registered in the current research. We evaluated short-term and long-term outcomes by measuring the percentage of the National Institutes of Health Stroke Scale (NIHSS) improvement and the modified Rankin Scale (mRS) at 3 months, respectively. We also assessed the chronic, sustained brain damage associated with cSVD using the total MRI burden and confirmed the relationship between prognosis and the total MRI burden of cSVD. Furthermore, we explored the associations between D-dimer and C-reactive protein (CRP) levels with NIHSS improvement and mRS at 3 months, as well as their relationships with both the total MRI burden of cSVD and its 4 imaging features.
RESULTS: Both NIHSS improvement and the mRS at 3 months were found to be correlated with the total MRI burden of cSVD. Higher D-dimer and CRP levels showed a linear correlation, indicating worse prognosis and a higher total MRI burden of cSVD. The four imaging features of the total MRI burden of cSVD did not exhibit entirely consistent patterns when exploring their correlations with prognosis and laboratory indicators.
CONCLUSION: Inflammation-associated D-dimer predicts neurological outcomes in patients with recent small subcortical infarct, and reflects a more severe total MRI burden of cSVD.
FIELD: psychiatry. SUBSTANCE: constitutional endogenous schizoids receive daily orally 20-40 mg sonapax, 4-8 mg etaperazine, and 10-20 mg teralene or intravenously 1.5-h drop-by-drop infusion of daily dose of neuroleptics. Epileptoids are given daily orally 5-10 mg phenazepame, 10-20 mg diazepame in combination with 100-200 mg finlepsin or intravenously 1.5-h infusion of 10 mg relanium. Cycloids are given daily per os average daily dose of antidepressants or intravenously drop-by-drop infusion of 20 mg amitriptiline. Interoids are intravenously infused 10 mg relanium for 1.5 h. EFFECT: accelerated formation of stable psychic structure of personality and prevented development of resistance to treatment. 3 ex